Asymmetric Transfer Hydrogenation of 1-Naphthyl Ketones by an ansa-Ru(II) Complex of a DPEN-SO2N(Me)-(CH2)2(η6-p-Tol) Combined Ligand
摘要:
The first second-generation designer Ru(II) catalyst 1b featuring an enantiopure N,C-(N-ethylene-N-methyl-sulfamoyI)-tethered (DPEN-k(2)N,N)/n(6)toluene hybrid ligand Is introduced. Using an SIC 1000 in HCO2H Et3N 5:2 transfer hydrogenation medium, secondary 1-naphthyl alcohols are obtained in up to >99.9% ee under mild conditions. Mechanistic factors are discussed.
The present invention relates to compounds of formula I:
1
wherein one of R
1
and R
4
is selected from the group consisting of H, and optionally substituted C
1-6
alkyl, C
3-7
cycloalkyl, C
3-7
cycloalkyl-C
1-4
alkyl, and phenyl-C
1-4
alkyl; and the other of R
1
and R
4
is an optionally substituted C
9-14
aryl group; R
2
and R
3
are either:
(i) independently selected from H, R, R′, SO
2
R, C(═O)R, (CH
2
)
n
NR
5
R
6
, where n is from 1 to 4 and R
5
and R
6
are independently selected from H and R, where R is optionally substituted C
1-4
alkyl, and R′ is optionally substituted phenyl-C
1-4
alkyl, or
(ii) together with the nitrogen atom to which they are attached, form an optionally substituted C
5-7
heterocyclic group; and their use as pharmaceuticals, in particular for treating conditions alleviated by the antagonism of a 5-HT
2B
receptor.
Palladium-Catalyzed Carbonylative Coupling of Aryl Iodides with Alkenylaluminum Reagents
作者:Bo Chen、Xiao-Feng Wu
DOI:10.1021/acs.orglett.9b02923
日期:2019.9.20
A highly reactive catalytic system for the carbonylativecoupling of aryliodides with alkenylaluminum reagents has been developed. Various β-substituted γ,δ-unsaturated ketones were produced under mild conditions in good to excellent yields even under ppm level of palladium catalyst. Notably, this also represents the first example on carbonylative transformation of alkenylaluminum compounds. Additionally
Compounds of formula (I) or pharmaceutically acceptable salts thereof, exhibit 5-HT
1A
agonism in addition to noradrenaline reuptake inhibition and optionally also 5-HT reuptake inhibition are useful for the treatment of obesity.
Compounds of formulae: (I), (II), (IIIa), (IIIb), (IVa) and (IVb): or a pharmaceutically acceptable salt thereof, for use as pharmaceuticals, in particular for the treatment of a condition alleviated by antagonism of a 5-HT
2B
receptor.